<i>Helicobacter pylori</i> antibody responses and evolution of precancerous gastric lesions in a Chinese population

Pan, Kai; Formichella, Luca; Zhang, Lian; Zhang, Yang; Ma, Junling; Li, Zhexuan; Liu, Cong; Wang, Yumei; Goettner, Gereon; Ulm, Kurt; Classen, Meinhard; You, Wei‐Cheng; Gerhard, Markus

doi:10.1002/ijc.28560

Cited by 48 publications

(40 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this context, Helicobacter pylori infection, smoking, and age have positive associations, whereas nonsteroidal anti-inflammatory drugs (NSAIDs), low salt intake, and a high-fiber diet have an inverse association with gastric cancer (Mohebbi et al, 2008;Yavari et al, 2008;Malekzadeh et al, 2009;Pan et al, 2014). In addition to environmental factors, genetic factors may contribute to this phenomenon by alteration of cellular activities such as DNA repair, inflammatory response, tumor suppression, and carcinogen metabolism (Bonequi et al, 2013;Kim et al, 2014).…”

Section: Introductionmentioning

confidence: 98%

Prevalence of gastric precancerous lesions among chronic dyspeptic patients and related common risk factors

Ajdarkosh

Sohrabi

Moradniani

et al. 2015

European Journal of Cancer Prevention

View full text Add to dashboard Cite

Gastric cancer is one of the leading causes of cancer-related deaths worldwide. Progression of gastric cancer follows several steps from gastritis to atrophy, intestinal metaplasia, dysplasia, and finally cancer. The aim of this study was to determine the prevalence of gastric precancerous lesions and related common risk factors in a group of chronic dyspeptic patients. A total of 688 chronic dyspeptic patients older than 40 years of age were consecutively enrolled. The exclusion criteria were pregnancy, and a history of gastric cancer and gastric surgery. A questionnaire including demographic and clinical data, smoking habits, alcohol use, NSAIDs, and regular aspirin use was completed for all patients. Upper endoscopy and gastric biopsy were performed for all of the participants according to the standard protocols. Upper endoscopy was performed for all of the participants and biopsies were taken according to the biopsy protocol. The specimens were examined in a blinded manner by two expert gastrointestinal pathologists. The mean age of the participants was 57.87±9.10 years; there were 361 (52.5%) women. The prevalence of intestinal metaplasia, gastric atrophy, dysplasia, and positive Helicobacter pylori infection was 19.8, 12.8, 3.2%, and 64.5%, respectively. Age and H. pylori infection showed a significant association with pathological findings (odds ratio=3.10, 95% confidence interval: 1.91-4.72 and odds ratio=3.56, 95% confidence interval: 2.30-5.53, respectively). According to the high prevalence of precancerous lesions in patients with chronic dyspepsia who were older than 40 years of age, upper endoscopy and gastric mapping sampling for the detection of these lesions is recommended in intermediate-risk to high-risk areas.

show abstract

Section: Introductionmentioning

confidence: 98%

Prevalence of gastric precancerous lesions among chronic dyspeptic patients and related common risk factors

Ajdarkosh

Sohrabi

Moradniani

et al. 2015

European Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…According to our previous results from the same intervention trial, the subjects with increasing number of H. pylori seropositive antibodies at baseline showed a higher risk for progression to gastric cancer (42). Both of these prospective studies suggested a potential preferential population for anti- H. pylori treatment in the subjects with multiple seropositive antibodies, especially FliD and HapA, for their higher risk of gastric cancer and easier eradication tendency.…”

Section: Discussionmentioning

confidence: 90%

Helicobacter pylori antibody responses in association with eradication outcome and recurrence: a population-based intervention trial with 7.3-year follow-up in China

Wang¹,

Zhang²,

Su³

et al. 2017

Chinese Journal of Cancer Research

Self Cite

View full text Add to dashboard Cite

ObjectiveTo identify serum biomarkers that may predict the short or long term outcomes of anti-Helicobacter pylori (H. pylori) treatment, a follow-up study was performed based on an intervention trial in Linqu County, China. MethodsA total of 529 subjects were selected randomly from 1,803 participants to evaluate total anti-H. pylori immunoglobulin G (IgG) and 10 specific antibody levels before and after treatment at 1-, 2- and 7.3-year. The outcomes of anti-H. pylori treatment were also parallelly assessed by13C-urea breath test at 45-d after treatment and 7.3-year at the end of follow-up. ResultsWe found the medians of anti-H. pylori IgG titers were consistently below cut-off value through 7.3 years in eradicated group, however, the medians declined in recurrence group to 1.2 at 1-year after treatment and slightly increased to 2.0 at 7.3-year. While the medians were significantly higher (>3.0 at 2- and 7.3-year) among subjects who failed the eradication or received placebo. For specific antibody responses, baseline seropositivities of FliD and HpaA were reversely associated with eradication failure [for FliD, odds ratio (OR)=0.44, 95% confidence interval (95% CI): 0.27–0.73; for HpaA, OR=0.32, 95% CI: 0.17–0.60]. The subjects with multiple positive specific antibodies at baseline were more likely to be successfully eradicated in a linear fashion (Ptrend=0.006). ConclusionsOur study suggested that total anti-H. pylori IgG level may serve as a potential monitor of long-term impact on anti-H. pylori treatment, and priority forH. pylori treatment may be endowed to the subjects with multiple seropositive antibodies at baseline, especially for FliD and HapA.

show abstract

“…Recently, Pan et al examined the relationship between seropositivity for CagA, VacA, GroEL, urease subunit A (UreA), γ-glutamyl transpeptidase (gGT) and HcpC and the development of gastric lesions during the follow-up period in patients with a risk for precancerous gastric lesions at baseline [47]. The presence of antibodies for each specific antigen was examined by using the recomLine H. pylori test system, which is a line immune assay.…”

Section: Cytotoxin-associated Gene a Antibodiesmentioning

confidence: 99%

Biomarkers for Helicobacter Pylori Infection and Gastroduodenal Diseases

Shiota

Yamaoka

2014

Biomark. Med.

View full text Add to dashboard Cite

Helicobacter pylori infection is a major cause of gastric cancer. Although identifying H. pylori infected subjects is the first approach for delineating the high-risk population for gastric cancer, the presence of H. pylori antibodies is not sufficient for gastric cancer screening. Among H. pylori infected subjects, only a minority of infected individuals develop gastric cancer. Serologic markers of H. pylori infection can serve as potential predictors for the development of gastric cancer. Serum or urinary H. pylori antibodies, cytotoxin-associated gene A antibodies, pepsinogen and microRNAs were reported to be associated with precancerous lesions or gastric cancer. In this review, we summarized the utilities and limitations of each strategy.

show abstract

Helicobacter pylori antibody responses and evolution of precancerous gastric lesions in a Chinese population

Cited by 48 publications

References 30 publications

Prevalence of gastric precancerous lesions among chronic dyspeptic patients and related common risk factors

Prevalence of gastric precancerous lesions among chronic dyspeptic patients and related common risk factors

Helicobacter pylori antibody responses in association with eradication outcome and recurrence: a population-based intervention trial with 7.3-year follow-up in China

Biomarkers for Helicobacter Pylori Infection and Gastroduodenal Diseases

Contact Info

Product

Resources

About